Why the study?
Does treatment with RAS blockers reduce urinary angiotensinogen levels in patients with chronic glomerulonephritis?
Population
70 chronic glomerulonephritis patients and 30 normal control subjects
Comparison
Renin-angiotensin system (RAS) blockers vs No RAS blockers and normal control subjects
Design
Cross-sectional
Authors
Loading...
RAS blockade was associated with lower UAGT in glomerulonephritis; leaves open its utility as intrarenal RAS biomarker pending prospective validation.
Does treatment with RAS blockers reduce urinary angiotensinogen levels in patients with chronic glomerulonephritis?
Urinary angiotensinogen is elevated in chronic glomerulonephritis and is suppressed by RAS blockers, suggesting its utility as a biomarker for intrarenal RAS activity.
Urushihara et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: